Patients with Attention Deficit Hyperactivity Disorder (ADHD) are often treated with the western medicine of atomoxetine hydrochloride. Although this drug can treat the symptoms of patients with ADHD, it is easy to produce drug resistance and adverse reactions in the long run. A safer and more effective treatment is needed. As a new psychotherapy method, visual communication has been gradually applied in the field of medical education. This study explores visual communication based on atomoxetine hydrochloride combined illustration design in patients with ADHD.

102 ADHD patients admitted to a hospital in Beijing from July to December 2022 were selected as research subjects and randomly divided into an experimental group and a control group, with 51 patients in each group. The control group was treated with atomoxetine hydrochloride, and the experimental group was designed for visual communication treatment with atomoxetine hydrochloride combined with illustration. Treatment effects were analyzed using the SNAP scale.

The SNAP score decreased after treatment and before treatment, and the score of the experimental group was lower than that of the control group, and the difference was statistically significant (P<0.05, P<0,01).

Using atomoxetine hydrochloride combined with illustration design visual communication to treat patients with ADHD can not only improve their attention and concentration, but also relieve their symptoms, help them to understand and remember information more easily, and improve the treatment effect.

National Social Science Fund project (No. 21BMZ037).